BIO Double Helix Sponsor
Sponsors

Company Profile

Cytochroma Inc.

Renal
Dermatology
Cancer

330 Cochrane Drive
Markham, ON L3R8E4
Canada
http://www.cytochroma.com 		Incorporated in 1996
32 Employees 		Privately Held

This Year's Highlights

  • Successfully completed Phase I clinical trial with CTA018 for treatment of secondary hyperparathyroidism.
  • Successfully completed Phase II clinical trial with CTA018 for the treatment of chronic plaque psoriasis.
  • Recently raised US$21 million in financing.

Anticipated Highlights

  • Initation of another clinical program in 2007 for a candidate in vitamin D insufficiency.
  • Final results of Phase I clinical trial with CTA018, being investigated for the treatment of secondary hyperparathyroidism.
  • Complete series C financing.

Corporate Mission

Cytochroma is a development stage specialty pharmaceutical company focused on the prevention and treatment of disorders related to Vitamin D insufficiency. The Company has an advanced portfolio of new therapies for Vitamin D insufficiency and secondary hyperparathyroidism associated with CKD. In addition, the Company is developing novel therapies to treat hyperproliferative disorders, such as cancer and psoriasis, and hyperphosphatemia.